Annual Report

The report describes Genmab's first full year of Arzerra sales, with DKK 54 million in royalty payments, and progress across its clinical pipeline. It highlights new collaborations with Lundbeck and Seattle Genetics, alongside an updated corporate strategy and cost reductions. The report also records a group workforce decrease from 309 to 189 employees during 2010 and outlines the company's CSR focus areas.